Ahmad Masri, MD, MS
Steve R. Ommen, MD
Hypertrophic Cardiomyopathy: The 3 Things You Need to Know
Michael Miller, MD, FACC, FAHA, FNLA
Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Aruna Pradhan, MD, MPH
James A. Underberg, MD
Adopting the New Therapeutic “Lineup” to Manage ASCVD - East
Josep Comin-Colet, MD, PhD
Beyond Anemia: Addressing Iron Deficiency in Patients with Heart Failure
Mark J. Alberts, MD
Matthew Jay Budoff, MD
Lawrence A. Leiter, MD
Omega-3 Icosapent Ethyl and Stroke Reduction in Atherosclerotic Vascular Disease
Murray Epstein, MD
Gates B. Colbert, MD, FASN
Considerations When Using a Potassium Binder in Patients with CKD
Peter van der Meer, MD, PhD
Pieter Martens, MD, PhD
New Perspectives on the Management of HFrEF: Iron Deficiency and Cardiac Remodeling
New Perspectives on the Management of HFrEF: Iron Deficiency and Cardiac Remode…
Peter Libby, MD
Prof. Kausik Ray, MBChB, MD, MPhil
Panel Discussion on AHA Symposium: Clinical Rundown—3 Hot Topic Sessions on ASCVD Risk Reduction
Panel Discussion on AHA Symposium: Clinical Rundown—3 Hot Topic Sessions on ASC…
Gregg C. Fonarow, MD
Andrew J. S. Coats, MD
Applying Key Updates from ESC/HFA to Managing Heart Failure
Keith C. Ferdinand, MD
Marco Metra, MD
Managing HK in HF: Navigating the Evolving Clinical Landscape
Ileana L. Piña, MD, MPH, FAHA, FACC
Javed Butler, MD, MBA, MPH
Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
From Guidelines to Practice: Key Updates From 2021 HFSA
Robert J. Chilton, DO
John R. Nelson, MD, FACC, FNLA, FASNC
Clinicians' Update on Omega-3s in ASCVD Risk Reduction
Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
A New Normal? COVID-19 and HF in Clinical Trials
George L. Bakris, MD
Rajiv Agarwal, MBBS, MD, FASN, BRCU
Bertram Pitt, MD
FIGARO-DKD and FIDELITY Analysis: Key Takeaways
Optimizing RAASi Therapy in Patients with Hyperkalemia: The Role of Potassium Binders
Optimizing RAASi Therapy in Patients with Hyperkalemia: The Role of Potassium B…
Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACP
Robert Toto, MD
Elevated Creatinine and AKI Are NOT Synonymous: Optimal RAASi Therapy Is Always the Goal
Elevated Creatinine and AKI Are NOT Synonymous: Optimal RAASi Therapy Is Always…
Erin D. Michos, MD, MHS, FACC, FAHA, FASE
Leslie Cho, MD
Clinician’s Update on Omega-3s in ASCVD Risk Reduction